

# 2021 PAVE REGIONAL MEETING

## PARTICIPANT BIOS (IN ALPHABETICAL ORDER)

### Alejandro Llanos, Universidad Peruana Cayetano Heredia, Peru

Alejandro Llanos is a surgeon and graduated from the Cayetano Heredia Peruvian University (UPCH). He holds a master's in Tropical Diseases from the University of Brasília, a doctoral degree in medicine from the UPCH and a Ph.D. in Epidemiology and Tropical Diseases from the University of London. Alejandro founded the investigation group for leishmaniasis and malaria at the Alexander von Humboldt Institute of Tropical Medicine and the Public Health and Administration Faculty at UPCH. Currently, he is a professor, the executive director at UPCH and an assistant doctor at the Cayetano Heredia National Hospital.

### Alex Menezes, Global Health Strategies

Alex Menezes is a senior vice president and leads GHS's office in Rio de Janeiro, Brazil. He has over 20 years of experience engaging a variety of stakeholders on public health policy and advocacy. Prior to joining GHS, he worked at the International AIDS Vaccine Initiative (IAVI), where he developed the organization's Brazil program. As a director for country and regional programs, he also provided technical oversight for IAVI's civil society and community engagement efforts in South Africa, Kenya, Uganda, China, and India. Alex was involved in Brazil's civil society response to AIDS as a program director for Grupo Pela Vidda-RJ, managing the organization's HIV prevention, care, and advocacy programs. He has also worked for Brazilian nongovernmental organization IDAC, where he supported a pioneering network to provide mental health care for AIDS patients and their families. He is a board member of AVAC, a New York-based HIV prevention advocacy organization. Alex has a degree in psychology from the Pontifical Catholic University of Rio de Janeiro as well as master's degrees in communications from New York University and the Federal University of Rio de Janeiro.

### Alexandra Cameron, Unitaid

Alexandra Cameron is the senior technical manager for malaria at Unitaid, an international organization that invests in innovations to prevent, diagnose, and treat HIV/AIDS, tuberculosis, and malaria more quickly, affordably, and effectively. She leads the development of the organization's malaria strategy, which serves to guide investment decisions. Prior to this, she worked for several years at the World Health Organization, primarily focused on research and policy guidance to support the management of national pharmaceutical prices. She has also worked at the Ministry of Health and Long-Term Care in Ontario, Canada, where she served in several roles including senior policy analyst for women's health and gender. She holds an honours bachelor of science in biochemistry from McMaster University, a master's degree in international public health from the University of Sydney, and a PhD in pharmaceutical sciences from the University of Utrecht.

### Angela Devine, Menzies School of Health Research

Angela Devine is a health economist with 10 years of experience in the economic evaluation and costs related to the management of infectious diseases. Angela's current research is focused on the cost-effectiveness of options for the management of vivax malaria. She investigates options for improving the safety and effectiveness of radical cure in a variety of geographical and epidemiological settings. Additional projects in

global health extend from malaria to HIV, tuberculosis, hepatitis B, antimicrobial resistance, and dengue. Methodological research interests include the joint costs and consequences of co-infections, the evaluation of productivity losses in low- and middle-income countries, and the development of online tools to address policy decisions. In addition to her role at Menzies, Angela is a lecturer at Charles Darwin University and holds an honorary position at the University of Melbourne, where she is part of the malaria team in the Centre for Epidemiology and Biostatistics and the Health Economics Unit.

### **Camilo Manchola, Global Health Strategies**

Camilo Manchola-Castillo holds a PhD in bioethics and has been a postdoctoral fellow in bioethics at the UNESCO Chair in Bioethics at the University of Brasilia. He joined GHS as a program manager after working for more than 7 years as a manager for training at the Brazilian National Commission on Research Ethics (CONEP) and as a technical consultant at the Science and Technology Department of Brazil's Ministry of Health. Camilo has also worked as a consultant for UNESCO's Regional Bureau for Science in Latin America and the Caribbean in areas related to bioethics and research ethics; as a professor, he has worked for more than 10 years, nationally and internationally, teaching public health, bioethics, and international relations.

### **Cássia Rangel, Ministry of Health, Brazil**

Cássia Rangel is the director of the Department of Immunization and Communicable Diseases (DEIDT) at Brazil's Ministry of Health (MoH). She holds a bachelor's degree in biomedicine from the Federal University of the State of Rio de Janeiro, a master's degree in public health and environment from the Fiocruz National School of Public Health (in the sub-area of environmental toxicology), and a specialization in health law by the Health Law Program from Fiocruz Brasília. She has experience in public health in the areas of health surveillance, public health emergency, toxicology, and health and environment. Prior to joining DEIDT/MoH, she worked at the Department of Science and Technology of the Ministry of Health.

### **Daniel Villela, Oswaldo Cruz Foundation, Brazil**

Daniel Villela is a Researcher at the Oswaldo Cruz Foundation (Fiocruz) and currently coordinates the Computer Science Program (PROCC/Fiocruz). He has experience in mathematical modeling and performance analysis, with particular interest in quantitative methods in epidemiology and ecology of vectors that are relevant to public health. Among his themes of interest, those that stand out are mathematical modeling of transmissible diseases, with a focus on vector transmissible diseases (malaria, dengue, chikungunya, zika); dynamic modeling of vector populations, focusing on seasonal, climate and spatial effects; and methods applied to health vigilance. Viella earned a master's from the Federal University of Rio de Janeiro and a PhD from Columbia University.

### **Diego Brito Sousa, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado**

Diego works at the Fundação de Medicina Tropical Doutor Heitor Vieira Dourado in collaboration with Escola Superior de Ciências da Saúde, Universidade do Estado do Amazonas in Manaus, Western Brazilian Amazon. His projects include clinical trials on the safety and effectiveness of alternative primaquine regimens for vivax malaria treatment in G6PD-deficient patients as well as implementation research, specifically

focusing on G6PD-deficiency screening by malaria health workers prior to primaquine treatment in *vivax* malaria—endemic areas of the Brazilian Amazon. Diego also carries out research on snakebite envenomation, notably regarding hemostatic disturbances, epidemiology, and clinical presentation.

### Elodie Jambert, Medicines for Malaria Venture

Elodie Jambert is a Director in Medicines for Malaria Venture's (MMV) Access and Product Management team, supporting product launches and uptake of new medicines for *vivax* malaria, particularly tafenoquine. Prior to joining MMV, Elodie worked with Médecins Sans Frontières for 12 years, where she gained extensive knowledge and experience with access issues related to medicines. Previously, Elodie worked with the US Centers for Disease Control and Prevention on immunization, and with the World Health Organization supporting National Medicines Regulatory Authorities. She has also worked as a hospital pharmacist in France and in a small public manufacturing and hospital control unit. Elodie holds a doctorate in pharmacy and various degrees in public health, hospital pharmacy, hospital hygiene and pharmaco-epidemiology.

### George Jagoe, Medicines for Malaria Venture

George Jagoe is the Executive Vice-President of Access and Product Management at Medicines for Malaria Venture (MMV). George leads MMV's Access team in supporting the launch and expanded uptake of new medicines that MMV helps bring to market. Before MMV, he was the first Country Director for the Clinton Foundation's HIV/AIDS Initiative in Mozambique, supporting access to antiretroviral treatments via the national health system. He has also worked in the pharmaceutical industry (AstraZeneca, Spain), in health system management (Kaiser Permanente and Aetna International, United States and Argentina), and in healthcare consulting (ChapterHouse, United States). Earlier in his career, he worked with ACCION International supporting micro-enterprise programs throughout Latin America. George earned a bachelor's degree from Harvard College and a master's degree in Healthcare Administration from Kellogg School of Management at Northwestern University.

### Iván Darío Florez, Universidad de Antioquía

Iván Darío Florez is a pediatrician with a master's degree in clinical sciences and a professor at the Department of Pediatrics and Childcare at the University of Antioquia. He has extensive experience as a researcher in systematic reviews, network meta-analysis, and the development and methodology of guidelines of clinical practice. He is the leader of the AGREE Enterprise (Appraisal of Guidelines for Research and Evaluation) and chair of the recommendations working group of the COVID-END initiative. He is also an assistant professor at McMaster University in Hamilton. Iván was recently appointed as a member of the conflict panel of the Cochrane organization, dedicated to reviewing scientific evidence to inform health decision-making in the world, being the only Latin American in this position.

### Jamil Barton, PATH

Jamil Barton is a Program Officer on PATH's Market Dynamics team. He serves as PAVE's Co-Regional Advisor in Latin America. Jamil has experience implementing and supporting malaria-focused public health initiatives and field work scaling entrepreneurial initiatives in microfinance, social enterprise and housing throughout Latin-America. Prior to joining PATH, he worked with the Clinton Health Access Initiative in Central

America to strengthen subnational malaria programs in Honduras and collaborate with the National Malaria Control Programs preparing to join the Inter-American Development Bank's Regional Malaria Elimination Initiative (RMEI). Jamil has also worked to scale social enterprise initiatives in Colombia, Paraguay, and Guatemala. Barton holds a master's in Public Administration from the London School of Economics, and a bachelor's in Economics and Public Policy from the University of Chicago.

### Janice Culpepper, Bill & Melinda Gates Foundation

Janice Culpepper is a Senior Program Officer on the Malaria Program Strategy Team in Global Health at the Bill & Melinda Gates Foundation. She manages the team's initiative for the development of drugs for the treatment and prevention of malaria. She oversees investments to support the portfolio of Medicines for Malaria Ventures as well as several grants to academic and research institutes. Prior to joining the foundation, she had more than 20 years of experience in the biotechnology industry managing research projects and strategic alliances with pharmaceutical companies. Janice completed post-doctoral fellowships at the University of California, San Francisco and at the DNAX Research Institute, Palo Alto. She received her PhD in Biological Chemistry from Harvard University and her bachelor's degree in Biology from Clark University.

### Jonathan Novoa, Medicines for Malaria Venture

Jonathan Novoa is a medical doctor who also holds a master's degree in international health with experience in management in different health programs focused on communicable and neglected diseases, especially malaria. He has worked as a national consultant on malaria and other vector-borne diseases in the Pan American Health Organization (PAHO) in Colombia. He also worked as a public health and health monitoring and evaluation expert in various countries for PAHO; the Global Fund to Fight TB, HIV and Malaria; Doctors Without Borders (MSF); PricewaterhouseCoopers; and the Swiss Tropical and Public Health Institute. He worked as a doctor and medical coordinator for MSF in Angola, Colombia, South Sudan, and Haiti, directing and coordinating various health programs in humanitarian contexts. Jonathan has been a chairman and board member of the Latin American MSF Association and Malteser Board of Directors Colombia. Recently, he has joined Medicines for Malaria Venture (MMV) as an interim *P. vivax* radical cure regional advisor.

### Liana Blume, Ministry of Health, Brazil

Liana Blume majored in biological sciences and has a master's degree in molecular biology from the University of Brasilia. She currently works at the Ministry of Health in the Program for the Prevention and Control of Malaria and Diseases Transmitted by Aedes, as the technician responsible for the diagnosis of malaria and international cooperation. Liana has experience in the area of public health and animal health, with an emphasis on epidemiology and surveillance systems, and in the area of biochemistry, with an emphasis on enzymology.

### Marcus Lacerda, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado

Marcus Lacerda is a member of the National Malaria Control Program's Technical Advising Committee and the Malaria Therapeutics Sub-Committee at the Ministry of Health. He is a consultant for the World Health Organization in *P. vivax* malaria and is an affiliated member of the Brazilian Science Academy. From 2015 to 2017, he served as president of the Brazilian Tropical Medicine Society. He majored in medicine at the

University of Brasilia, with a medical residence in infectiology at the Tropical Medicine Foundation. Marcus holds a doctorate in tropical medicine from the University of Brasilia in partnership with New York University.

### **Maria Paz Adé, Pan American Health Organization**

Maria Paz Ade is a Malaria Advisor at the Pan American Health Organization's (PAHO) Diagnostics and Supply Management Department within the malaria program. At PAHO, she has held several positions at the Department of Communicable Diseases and Environmental Determinants of Health in the Regional office of the Americas and in El Salvador, PAHO/WHO country office. Previously, Maria Paz has worked in the areas of laboratory and epidemiology within the infectious diseases' programs for TB and HIV/Aids in Paraguay. She holds a bachelor's degree in Biology from the National University of Asunción and a doctor's degree in Microbiology from the Autonomous University of Bellaterra.

### **Matthew Steele, Bill & Melinda Gates Foundation**

Matthew Steele is a senior program officer at the Bill & Melinda Gates Foundation in the Global Delivery Programs. His work spans three focal areas. First, he leads efforts to prepare for and respond to outbreak diseases with vaccines, enhanced surveillance, mathematical modeling, and innovative human and logistical approaches to identification and control of these diseases. Second, he leads randomized clinical trials to critically assess the potential impact of biannual (or other frequency) single-dose antibiotic administration to reduce all-cause child mortality in the Sahel. Current funded studies are ongoing in Niger and Burkina Faso with technical assistance to efforts in Nigeria, Côte d'Ivoire, and Mali. Finally, Matthew is the program officer for a global program (led by PATH and MMV) to enhance identification, control, and cure of *P. vivax* malaria infections using new drug, diagnostic, and modeling tools.

### **Michael White, Institut Pasteur**

Michael White is a researcher at the Institut Pasteur's Malaria: Parasites and Hosts Unit. The core of his expertise lies in the epidemiology and mathematical modelling of malaria, with a particular focus on *P. vivax*. He has developed a wide range of statistical methods for the analysis of sero-epidemiological data from studies of malaria and neglected tropical diseases. Prior to joining Institut Pasteur, Michael was a visiting scientist in The Walter and Eliza Hall Institute in Melbourne, Australia, and a postdoc in Imperial College London in the UK.

### **Michelle Hsiang, University of California, San Francisco**

Michelle Hsiang is an associate professor in the Department of Epidemiology and Biostatistics, Division of Infectious Diseases and Global Epidemiology, with a secondary appointment in the Department of Pediatrics, Division of Pediatric Infectious Diseases. She serves as the director of research for the Malaria Elimination Initiative at the Institute for Global Health Sciences. She was an inaugural member of the Malaria Elimination Group (MEG) and co-founded the Asia Pacific Malaria Elimination Network (APMEN). She is a WomenLift Leader in Global Health through Stanford and the Bill & Melinda Gates Foundation's program WomenLift Health. She studied human biology as an undergraduate at Stanford University and attended medical school at Baylor College of Medicine. Michelle trained in pediatrics and pediatric infectious diseases at the University of California, San Francisco, and obtained a master's degree in epidemiology at the London School of



Hygiene and Tropical Medicine. From 2012 to 2021, she was an assistant professor in pediatrics at UT Southwestern Medical School, where she was also a Horchow Family Endowed Scholar in pediatrics.

### Nick Luter, PATH

Nick Luter is a senior market dynamics officer in PATH's Market Dynamics program, leading market access work related to malaria, including the *P. vivax* focused PAVE project. Prior to joining PATH, Nick attended Johns Hopkins School of Advanced International Studies, earning a master's in International Relations and Economics. Previously, he worked with Results for Development on projects focusing on growing private sector access to malaria rapid diagnostic tests and access to pneumonia treatments. Nick also gained experience with Frontier Strategy Group and the hedge fund division of Guggenheim Partners. Luter holds a bachelor's in international affairs and international economics with a minor in French from the University of Colorado.

### Ray Cummings, PATH

Ray Cummings is Director of PATH's Market Dynamics Program, which conducts market analytics and develops and implements strategies for strengthening markets and improving access to healthcare products in low-and middle-income countries. Ray serves on the leadership team of PATH's Center for Malaria Control and Elimination. Prior to assuming his current position, Ray was Commercialization Director of PATH's Drug Development Global Program and Senior Business Officer in PATH's Vaccine and Pharmaceutical Technologies Group. He has 25 years of experience in commercial and executive leadership roles in the pharmaceutical and biotechnology industries, including positions at Sarepta Therapeutics, Pfizer, and Amgen. Cummings received his MBA from the University of California, Berkeley and his master's in biochemistry and molecular biology from Harvard University.

### Roberta Ataides, Global Health Strategies

Roberta is a director at the GHS Rio office. She joined GHS after working as a technical consultant at the Science and Technology Department of Brazil's Ministry of Health, as a prevention programs coordinator at the National Secretariat on Drug Policies of Brazil's Ministry of Justice, and as a health and development program assistant at the United Nations Office on Drugs and Crime. Before that, she worked as a program assistant at UN Women and as a researcher at Fiocruz Brasilia. Over the years, she managed several research projects to improve the public health system in Brazil and implemented development projects on HIV/AIDS, mental health, drug use prevention and care, and gender equality. Roberta holds a bachelor's degree in international relations from the Catholic University of Brasilia, and a master's degree in bioethics from the University of Brasilia.

### Roberto Montoya, Pan American Health Organization

Roberto Montoya is the Regional Malaria Advisor within the Department of Communicable Diseases of the Pan American Health Organization (PAHO). He has held positions in the areas of epidemiology and the control of vector-borne diseases at the Ministry of Health of Colombia and as an Associate Researcher at the Universidad de los Andes. Roberto has also worked as PAHO coordinator of the Amazon Network for the Surveillance of Antimalarial Resistance (RAVREDA) and later held positions in surveillance and control

of communicable diseases in the PAHO offices in Colombia and Ecuador. Roberto has majored in medicine at the Javeriana University of Bogotá and holds a doctor's degree in tropical medicine from the Oswaldo Cruz Foundation.

### **Sheila Rodvalho, Pan American Health Organization, Brazil**

Sheila Rodvalho is a Technical Consultant in malaria for the Brazilian office of the Pan American Health Organization. Previously, she worked as a Technical Consultant within Brazil's National Malaria Control Program, when she acted as focal point for interactions between the NMCP and points of care and oversaw epidemiological monitoring for all Amazon states and municipalities. Sheila holds a bachelor's degree in biological sciences and a master's degree in ecology from the University of Brasilia.

### **Sonia Herrera, University of California, San Francisco**

Sonia is a postdoctoral fellow on vaccine development at the Department of Molecular Microbiology and Immunology at Johns Hopkins University and a researcher at the University of California, San Francisco. She has focused her work on malaria surveillance and education for health promotion and prevention of malaria in endemic regions along the Pacific coast in Columbia. Sonia also worked on Zika during the Colombian outbreak in 2016 and 2017, reporting cases to the Colombian Ministry of Health and researching in the same area.

### **Stephanie Zobrist, PATH**

Stephanie Zobrist is a public health researcher focused on the development and introduction of global health technologies. She currently works as a Program Officer with PATH's global diagnostics program, where she leads and supports clinical and user research for diagnostic products, including evaluations of diagnostics for performance, usability, and operational feasibility.